Back to Search Start Over

Surface antigen serocleared hepatitis B virus infection increases the risk of mixed cryoglobulinemia vasculitis in male patients with chronic hepatitis C.

Authors :
Morrone A
Fiorilli V
Cinti L
Roberto P
Ferri AL
Visentini M
Pulsoni A
Spinelli FR
De Santis A
Antonelli G
Basili S
Tosti ME
Conti F
Casato M
Source :
Frontiers in immunology [Front Immunol] 2024 Jul 11; Vol. 15, pp. 1411146. Date of Electronic Publication: 2024 Jul 11 (Print Publication: 2024).
Publication Year :
2024

Abstract

Mixed cryoglobulinemia vasculitis (MCV) is caused in ~90% of cases by chronic hepatitis C virus (HCV <superscript>pos</superscript> MCV) and more rarely by hepatitis B virus (HBV) infection, or apparently noninfectious. HCV <superscript>pos</superscript> MCV develops in only ~5% of patients with chronic hepatitis C (CHC), but risk factors other than female gender have not been identified so far. We conducted a retrospective case control study investigating whether past active HBV infection, defined by hepatitis B surface antigen (HBsAg) seroclearance and anti-core antibody (HBcAb) positivity, could be a risk factor for developing HCV <superscript>pos</superscript> MCV. The prevalence of HBsAg seroclearance was 48% within 123 HCV <superscript>pos</superscript> MCV patients and 29% within 257 CHC patients (p=0.0003). Multiple logistic regression including as variables gender, birth year, age at HBV testing, cirrhosis, and hepatocellular carcinoma, confirmed an association of HBsAg seroclearance with HCV <superscript>pos</superscript> MCV [adjusted odds ratio (OR) 2.82, 95% confidence interval (95% CI) 1.73-4.59, p<0.0001]. Stratification by gender, however, showed that HBsAg seroclearance was associated with HCV <superscript>pos</superscript> MCV in male [OR 4.63, 95% CI 2.27-9.48, p<0.0001] and not in female patients [OR 1.85, 95% 95% CI 0.94-3.66, p=0.076]. HBsAg seroclearance, and more likely occult HBV infection, is an independent risk factor for HCV <superscript>pos</superscript> MCV in male CHC patients.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.<br /> (Copyright © 2024 Morrone, Fiorilli, Cinti, Roberto, Ferri, Visentini, Pulsoni, Spinelli, De Santis, Antonelli, Basili, Tosti, Conti and Casato.)

Details

Language :
English
ISSN :
1664-3224
Volume :
15
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
39055707
Full Text :
https://doi.org/10.3389/fimmu.2024.1411146